trivalent inactivated influenza vaccine + inactivated H1N1 vaccine

This combination consists of a licensed seasonal trivalent inactivated influenza vaccine (TIV) and a monovalent unadjuvanted inactivated H1N1 pandemic influenza vaccine. Developed and evaluated by the National Institute of Allergy and Infectious Diseases (NIAID) in response to the 2009 H1N1 pandemic, the combination was studied to assess the safety and immunogenicity of concurrent versus sequential administration. The H1N1 component was manufactured by Sanofi Pasteur and CSL Biotherapies. The vaccines function by presenting inactivated viral hemagglutinin antigens to the immune system, stimulating the production of neutralizing antibodies to prevent infection from seasonal H1N1, H3N2, and B strains, as well as the pandemic A/California/07/2009 (H1N1) strain. Clinical findings indicated that simultaneous administration did not impair the effectiveness of either vaccine component.

Other names

trivalent inactivated influenza vaccine + inactivated H1N1 vaccineH1N1 and Seasonal Flu Vaccine Co-administrationH-1N1 and Seasonal Flu Vaccine Co-administrationH 1N1 and Seasonal Flu Vaccine Co-administrationseasonal trivalent influenza vaccine + pandemic H1N1 vaccine